Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sidley Austin recruits Senger

This article was originally published in The Tan Sheet

Executive Summary

FDA's former acting chief counsel and deputy chief counsel Jeffrey Senger joins Sidley Austin's global food, drug and medical device regulatory practice in Washington. The firm's new partner "has an internal understanding of the FDA, combined with a handle on the complex regulatory and enforcement environments in which we work," said Raymond Bonner of Sidley's executive committee. The firm said Aug. 2 Senger also served 17 years in the Department of Justice. He was replaced as acting chief counsel at FDA in April 2009 by Michael Landa, now acting director of the Center for Food Safety and Applied Nutrition (1"The Tan Sheet" April 13, 2009)

You may also be interested in...



Expected Pick For FDA Acting Chief Counsel Has CFSAN Experience

The anticipated selection of Michael Landa as FDA acting chief counsel indicates the Obama administration places a premium on food and device legal expertise in addition to substantive agency experience

Crunch Time For Protection Of New Therapeutic Uses In Europe

The pharmaceutical industry will be watching carefully as the EU Court of Justice deliberates on whether to deny or widen the granting of supplementary protection certificates on new therapeutic indications of authorized medicines.

Dr Reddy’s Posts Surprise Q3 Loss With NuvaRing Write-Off

Dr Reddy’s Laboratories reported an unexpected third-quarter consolidated net loss after taking a $156m charge related to its generic version of the NuvaRing contraceptive. However, the company’s shares jumped on a robust underlying performance that was praised by analysts.

Topics

UsernamePublicRestriction

Register

PS104413

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel